Scancell: Response to Press Speculation

Summary by AI BETAClose X

Scancell Holdings plc is in advanced discussions for a potential reverse merger with Neuphoria Therapeutics Inc. through an all-share transaction, which could facilitate a Nasdaq listing and increase its profile with US specialist investors. Concurrently, Scancell is exploring equity and debt financing to support a global Phase 3 registrational study for its lead asset, iSCIB1+. The outcome of these discussions and financing remains uncertain, and further announcements will be made as appropriate.

Disclaimer*

UK 100

Latest directors dealings